Pharmaceutical, Healthcare and Payer Business Solutions

Block

DEMO

PAYER, PROVIDERS AND PHARMACIES

HEALTHCARE

PHARMA

We Answer the “What” and the “Why” of

Market Access.

LET'S TALK

Solutions for Pharmaceutical Manufacturers

Our customers rely on our industry-leading data and insights and cutting-edge technology to overcome barriers to access.

LEARN MORE

Solutions for
Healthcare IT

Let our unbeatable covered lives methodology and innovative technology inform your market access strategy.

LEARN MORE

Solutions for Payers, Providers and Pharmacies

Establish reimbursement policies, formulary positioning and access financial assistance that make therapies affordable for patients.

LEARN MORE

Directory of Health Plans

Your source of truth for payer market share. Try out the Directory of Health Plans demo today.

ACCESS THE DEMO

Slide 1

Insights

The 2024 State of Patient Access

MMIT interviewed more than 300 pharma and biotech leaders to learn what keeps them up at night—and what gets them going in the morning. Read on for the survey findings and expert analysis.

LEARN MORE

Slide 1

Insights

Unleash the Power of Real-World Data

MMIT helps pharma companies harness the power of real world data to better understand the patient journey.

LEARN MORE

Slide 1

HCP Targeting Report

Find High-Value HCPs for Your Therapy

One of the first steps in your therapy’s commercialization journey should be to identify high-value HCPs who can help guide valuation, messaging and more.

LEARN MORE

Slide 1

Insights

Intelligent Insights

Our Zitter Insights Panel uses research to illuminate the complexities of market access.

LEARN MORE

Slide 1

Industry Leading Insights

MMIT offers a range of publications for pharma, payers and providers covering news, strategy and insights across the spectrum. Our in-house journalism division AIS Health provides objective news and analysis of industry trends while RJ Health provides a comprehensive look at industry updates as they apply to medically covered drug reimbursement processes.

Slide 5

"We need doctors to fight the good fight so that any patient who needs the therapy can get the therapy, and MMIT plays a key role in that process. We need you to help us fulfill our mission for our patients."

Vice President of Market Access

Small Pharma Company

Slide 2

"As a small company, we appreciate the flexibility and responsiveness of the MMIT team. Their customer support team has done a great job working with our new hires to get them trained on their solutions."

Mark Devlin

Vice President, Head of Market Access | Phathom Pharmaceuticals

Slide 1

“Ryan [Witherington] and the team at MMIT have been great partners in our initiatives to analyze and communicate payer policy data for our product through innovative field tools, both MMIT-developed and developed by us using MMIT data. FormTrak Web, in particular, has been well-received by our field sales team and we are excited to transition to FormTrak in Veeva to streamline the process and make it an even more valuable tool.”

Director of Market Access

Large Pharma Company

Slide 3

“DHP provided us a list that was stronger than what we typically begin with, which, in turn, lowered the amount of time spent on payer that didn’t fit our profile.”

Erin Studstill

Vice President of Operations and Technology | MarketLauncher

Slide 4

"Throughout my 10 years in market access, I've been exposed to most of the top solutions, at times simultaneously. I've always found myself turning to MMIT because of their products' ease of use and data integrity."

Jai Persico

National Account Executive | Neurocrine Biosciences

TL 4

Thought Leadership

Open vs. Closed Claims: Unlocking Opportunities for Healthcare Analytics

In the complex healthcare analytics landscape, understanding the nuances of open and closed claims is critical for researchers and analysts. Open and closed claims each offer unique insights into the patient journey.

TL 6

Thought Leadership

Acing Market Access: Six Steps to Take Before Launch

Our first post in this series discussed how early market access research, conducted in the 12-18 months before launch, helps pharma companies identify differentiators and establish accurate expectations.

Market-Access-Six-Steps-Take-Before-Launch

TL 5

Thought Leadership

Digital Best Practices for Communicating Drug Coverage to HCPs

Before physicians prescribe a new therapy, they need to trust that it is the most effective and appropriate treatment for an individual patient.

Digital-Best-Practices-Communicating-Drug-Coverage-HCPs

TL 1

Thought Leadership

Key Benefits of Early Market Access Planning

According to our 2024 State of Patient Access survey, 81% of pharma companies are launching their market access planning much earlier than they did five years ago.

Key-Benefits-Early-Market-Access-Planning

TL 2

Thought Leadership

Tremendous Growth in 2024 Health Insurance Exchange Membership

For the past year, Medicaid has been the predominant topic of conversation for those who monitor insurance market share shifts

Tremendous-Growth-2024-Health-Insurance-Exchange-Membership

TL 3

Thought Leadership

When Payers Become Producers: Inside the Private-Labeling Trend

Vertical integration between payers, PBMs, specialty pharmacies, and providers has grown in the last decade, with more negotiating power concentrated among a handful of major players.

Subscribe to MMIT's Thought Leadership

Get the latest from MMIT’s leading subject matter experts, receiving the latest posts right to your inbox. Top-quality thought leadership 100% free.

subscribe today

News and Media

Specialty Pharmacy Continuum

What Keeps Pharmacy Stakeholders Up at Night?

August 23, 2024

At Asembia's AXS24 Summit, MMIT's Dinesh Kabaleeswaran and The Dedham Group's Jen Klarer presented on the results of the 2024 State of Patient Access survey. In this article, Specialty Pharmacy Continuum shares key points from their presentation.

Fierce Healthcare

PBMs Defend Business Practices — But Lawmakers Aren’t Convinced

July 23, 2024

The House Committee on Oversight and Accountability held a hearing on the business practices of the three largest PBMs. Fierce Healthcare tapped MMIT’s Andrew Rouff for commentary on the investigation into whether PBMs are responsible for inflating drug prices.

Life Science Leader

Patient Access Challenges Are Changing Pharma Investment Strategies

July 9, 2024

Patient access issues across the value chain are prompting manufacturers to invest in early-stage market access planning using real-world data. MMIT's Dinesh Kabaleeswaran and The Dedham Group's Jen Klarer explain these industry shifts.

M&MM

Patient Access Challenges Are Changing Pharma Investment Strategies

June 2, 2024

Eli Lilly's drug will be marketed under the brand name Kisunla for treating adults with early symptomatic Alzheimer’s disease. MM&M asked MMIT's Chief Clinical Officer Jayne Hornung for commentary on this exciting news.

Pharma Executive

Pharmaceutical Executive

Today’s New Messaging Mix: The State of Pharma Marketing in 2024

May 13, 2024

At a Pharmaceutical Executive roundtable event on the state of marketing in the pharmaceutical industry, MMIT's Jay Shah and Skipta's Glen Saunders shared their thoughts on digital strategies, the use of AI, and the impact of med-legal regulations on marketing campaigns.

ISJR Paper

International Journal of Science and Research

Evaluating the Role of AI and Identifying Use-Cases in U.S. Managed Care Organizations

April 2024

This research paper explores how payers’ familiarity with AI tools and explores the likelihood of AI implementation to reduce administrative burden across managed care and government organizations.

Press Release

MMIT Announces Finalists of the Ninth Specialty Pharmacy Patient Choice Awards

March 20, 2024

Managed Markets Insight & Technology (MMIT), the trusted go-to-market partner for overcoming barriers to patient access, has announced the finalists of its ninth Specialty Pharmacy Patient Choice Awards.

Drug Channels

Copay Accumulator and Maximizer Update: Adoption Expands as Legal Barriers Grow

February 14, 2024

This review of current benefit designs uses MMIT’s data on commercial plans’ use of copay accumulators and maximizers.

ISJR Paper

International Journal of Science and Research

Evolving Site of Care Trends in the U.S. Managed Care Ecosystem

January 20, 2024

The movement of care from high-cost, post-acute sites to lower-cost freestanding and non-acute sites has accelerated. This research paper explores the impact of payer site-of-care preferences across payers, oncologists and physicians.

Pharma Executive

Pharmaceutical Executive

Building Awareness of Anti-Obesity Drugs: 2024 Trends

January 18, 2024

The increased popularity of anti-obesity medications is raising questions about inequities in patient access, due to both shortages and limited payer coverage policies.

Healthcare IT Today

Uses of AI in Healthcare: 2024 Health IT Predictions

January 17, 2024

The application of AI will expand into managed care organizations in the near future. For payers and PBMs, AI tools can be useful for tasks including claims processing, prior authorization review, and data retrieval.

Healthcare IT Today

The American Journal of Managed Care

Navigating the Biosimilar Frontier: Opportunities and Challenges in 2024

January 14, 2024

Biosimilars offer substantial promise for a new era of accessibility and affordability for patients, but better understanding of these products from payers and providers is necessary for biosimilars to reach their full potential.

Pharmacy Times

Claims, Lab, And EHR Data Can Make Or Break A Drug Launch

January 2, 2024

By blending claims, lab, and EHR data with payer coverage and clinical pathway data, pharma companies can gain full visibility into what’s happening in the market before they launch.

Press Release

MMIT Wins Titan Health Award for Healthcare Innovation

December 4, 2023

Patient Access Analytics received the Gold Award for Technology Solutions in Healthcare.

in Vivo

In Vivo

Worries And Hopes For Health Care Delivery In 2024

November 29, 2023

Life sciences companies will face several challenges in the new year, from more pressure on pipelines to the ongoing consequences of regulatory changes. Norstella experts share their predictions.

BioPharma Dive

Using Real-World Data To Improve Patient Access To Oncology Therapies

October 9, 2023

Many oncology manufacturers assume that a therapy’s inclusion on clinical pathways is more important than its coverage profile, but this isn’t always true.

Drug Channels

How Payers Are Reacting To Insulin Price Changes

September 15, 2023

Insulin price caps and list price reductions are a huge step forward for patient access. But what will these changes mean for health plans?

Contract Pharma

Solving Pharma’s Underlying Rebate Leakage Problem

September 13, 2023

Rebate leakage drains millions in revenue from pharma companies every year. To ensure contract compliance, manufacturers can implement these five steps.

Payer Data Intelligence Solutions

Payer and Provider Insights Solutions

Payer Solutions

Promotional Solutions

Specialty Pharmacy Solutions

Market Access

Patient Journey

Brand Performance and Strategy

Contracting and Reimbursement

"We need doctors to fight the good fight so that any patient who needs the therapy can get the therapy, and MMIT plays a key role in that process. We need you to help us fulfill our mission for our patients."

Vice President of Market Access

Small Pharma Company

"As a small company, we appreciate the flexibility and responsiveness of the MMIT team. Their customer support team has done a great job working with our new hires to get them trained on their solutions."

Mark Devlin

Vice President, Head of Market Access | Phathom Pharmaceuticals

Director of Market Access

Large Pharma Company

“DHP provided us a list that was stronger than what we typically begin with, which, in turn, lowered the amount of time spent on payer that didn’t fit our profile.”

Erin Studstill

Vice President of Operations and Technology | MarketLauncher

"Throughout my 10 years in market access, I've been exposed to most of the top solutions, at times simultaneously. I've always found myself turning to MMIT because of their products' ease of use and data integrity."

Jai Persico

National Account Executive | Neurocrine Biosciences

Subscribe to MMIT's Thought Leadership